Siga’s Tpoxx Safe for Monkeypox Patients, Early Study Shows

Siga Technologies Inc.’s antiviral Tpoxx is safe when used to treat symptoms of monkeypox, according to an early study that provides evidence for its use in helping alleviate painful sores caused by the viral disease that’s infected at least 20,000 Americans.

Tpoxx only has US Food and Drug Administration clearance for use against smallpox, and at the time the study was done, clinicians were required to follow up with patients after prescribing it for monkeypox. Reports indicated that only 3.5% of patients reported reactions to the medication, and all but one were non-serious. The findings were published Friday by the US Centers for Disease Control and Prevention.